Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;3(4):230-235.
doi: 10.1007/s40610-017-0079-1. Epub 2017 Oct 23.

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer

Zoran Culig  1
Affiliations
Review

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer

Zoran Culig. Curr Mol Biol Rep. 2017.

Abstract

Purpose of review: Compensatory mechanisms leading to increased androgen receptor expression and activity after androgen ablation or anti-androgen treatment have been identified in prostate cancer. After hydroxyflutamide and bicalutamide were used in therapy of prostate cancer over many years, novel anti-androgen enzalutamide showed improved clinical activity. However, enzalutamide resistance develops over a certain time period, and molecular mechanisms responsible for this process are heterogeneous.

Research findings: As with other anti-androgens, these mechanisms include alterations of AR but also may be associated with overexpression of oncogenes which should be targeted by novel therapies. Androgen receptor splice variants have been frequently described in patients who developed enzalutamide resistance. Mutant AR F876L has been detected in patients who are resistant to enzalutamide. Glucocorticoid receptor overexpression has been observed in patient tissues and in pre-clinical models of enzalutamide resistance.

Summary: There is a heterogeneous picture of enzalutamide resistance in prostate cancer and, therefore, the development of appropriate post-enzalutamide treatment remains a challenge.

Keywords: Anti-androgens; Cytokines; Enzalutamide; Mutations; Truncated androgen receptor.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Zoran Culig declares research funding and honoraria from Astellas outside the submitted work.

Human and Animal Rights and Informed Consent

This article contains no studies with human or animal subjects performed by any of the authors.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS. Enzalutamide versus bicalutamide in castration-resistant prostate cancer. The STRIVE trial. J Clin Oncol. 2016;34:2098–2106. doi: 10.1200/JCO.2015.64.9285. - DOI - PubMed
    1. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483–489. doi: 10.1158/0008-5472.CAN-12-3630. - DOI - PMC - PubMed
    1. Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD. Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer. Clin Cancer Res. 2016;22:4466–4477. doi: 10.1158/1078-0432.CCR-15-2901. - DOI - PMC - PubMed
    1. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, et al. The androgen receptor coactivator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 2004; 159–66. - PubMed
    1. Kato M, Banuelos CA, Imamura Y, Leung JK, Caley DP, Wang J, Mawji NR, Sadar MD. Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer. Clin Cancer Res. 2016;22:2744–2754. doi: 10.1158/1078-0432.CCR-15-2119. - DOI - PMC - PubMed

LinkOut - more resources